1888 PressRelease Home	Sign In	Sign Up	Contact Us	About Us	Sitemap

1888 Press Release | Dr.reddy's Laboratories Ltd Press Releases

Drreddys.com - Dr.reddy's Laboratories Ltd Company News Section

Dr.reddy's Laboratories Ltd Information

Mythili

Phone: +91-40-66511620
URL: http://www.drreddys.com/

Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular and cancer.(http://www.drreddys.com/)

Dr.reddy's Laboratories Ltd Press Release -

Drreddys.com

23 JAN	Dr. Reddy’s Announces Settlement Of Exelon (Rivastigmine Tartrate) ANDA Litigation With Novartis
	Dr Reddy’s Laboratories (NSE: RDY) today announced that it has entered into a settlement agreement with Novartis Pharma AG.

23 JAN	Dr. Reddy's Launches Supanac® - (Diclofenac Potassium)
	Dr. Reddy’s has launched Supanac ® (Diclofenac potassium immediate release 50 mg tablets) in India, increasing its offering in the Rs 2700 crores (~ $688 million) NSAID market. (Source: IMS ORG June MAT ’07).

11 DEC	Argenta Discovery And Dr Reddy’s Progress Pre-clinical Anti-inflammatory Candidate To Treat Chronic Respiratory Disease
	Argenta Discovery Limited, the respiratory drug discovery and development company, and Dr Reddy’s Laboratories (NYSE: RDY), today announce a major milestone in their development programme targeting a novel disease-modifying approach to treat the underlying cause of certain chronic respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma.

27 NOV	Sygnis AG And Dr Reddys Pharmaceutical Company Sign Exclusive Supply Collaboration For AX200 In Stroke
	Agreement with Dr. Reddy’s secures long-term supply to advance the clinical development of SYGNIS’ lead product candidate -- Dr. Reddy’s first agreement for the long-term supply of a biological molecule; First of its kind from India

21 NOV	Dr.reddy’s Pharmaceutical Company Q2 Fy08 Revenue At Rs 12,670 Million
	Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited financial results for the quarter ended September 30, 2007

06 NOV	Dr. Reddy's Pharmaceutical Company To Release Q2 Fy08 Results On October 24, 2007
	Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the second quarter ended September 30, 2007 on Wednesday, October 24, 2007 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com

11 OCT	Dr. Reddy's Pharmaceutical Company Commences Operations In Philippines
	Dr. Reddy's Pharmaceutical Company Commences Operations in Philippines. Expands presence in the ASEAN region

15 SEP	Dr. Reddy's Receives USFDA Approval For Ranitidine (Zantac™) Tablets, 150mg (OTC) - First Major Approval For Its U.S. OTC Business
	Dr. Reddy’s Laboratories (NYSE:RDY) announced today, that the U.S. Food and Drug Administration (USFDA) has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) for Ranitidine (Zantac™) 150mg tablet (Over-the-Counter).